You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 14, 2025

PEGINTRON Drug Profile


✉ Email this page to a colleague

« Back to Dashboard


Recent Clinical Trials for PEGINTRON

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Rockefeller UniversityPhase 1
Luis MontanerPhase 1
Philadelphia FightPhase 1

See all PEGINTRON clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for PEGINTRON Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for PEGINTRON Derived from Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Merck Sharp & Dohme Llc PEGINTRON peginterferon alfa-2b Injection 103949 5,395,760 2010-05-10 Company disclosures
Merck Sharp & Dohme Llc PEGINTRON peginterferon alfa-2b Injection 103949 5,605,690 2015-02-08 Company disclosures
Merck Sharp & Dohme Llc PEGINTRON peginterferon alfa-2b Injection 103949 5,618,698 2015-06-06 Company disclosures
Merck Sharp & Dohme Llc PEGINTRON peginterferon alfa-2b Injection 103949 5,908,621 2017-04-29 Company disclosures
Merck Sharp & Dohme Llc PEGINTRON peginterferon alfa-2b Injection 103949 5,945,397 2016-05-16 Company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for PEGINTRON Derived from Patent Text Search

These patents were obtained by searching patent claims

Supplementary Protection Certificates for PEGINTRON

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C300008 Netherlands ⤷  Try for Free PRODUCT: ETANERCEPTUM
SPC/GB00/015 United Kingdom ⤷  Try for Free PRODUCT NAME: ETANERCEPT; REGISTERED: CH 55365 20000201; UK EU/1/99/126/001 20000203
10075011 Germany ⤷  Try for Free PRODUCT NAME: ENBREL-ETANERCEPT; NAT. REGISTRATION NO/DATE: EU/1/99/126/001 20000203; FIRST REGISTRATION: CH (LI) 55365 20000201
132000900852970 Italy ⤷  Try for Free
0090011-8, 0091011-7 Sweden ⤷  Try for Free NATIONAL REGISTRATION NO/DATE: EU/1/99/126/001 20000203; FIRST REGISTRATION: LI 55365 20000201
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Market Dynamics and Financial Trajectory for the Biologic Drug: PEGINTRON

Last updated: July 8, 2025

Introduction to PEGINTRON

PEGINTRON, a pegylated interferon alpha-2b developed by Merck (formerly Schering-Plough), has played a pivotal role in treating chronic hepatitis C since its approval by the FDA in 2001. As a biologic drug, it combines interferon with polyethylene glycol to enhance its efficacy and prolong its half-life, making it a cornerstone therapy before the advent of direct-acting antivirals. This article examines the current market dynamics and financial trajectory of PEGINTRON, offering business professionals actionable insights into its evolving landscape amid competition, patent challenges, and shifting healthcare demands.

Overview of PEGINTRON's Market Dynamics

The global hepatitis C market, valued at approximately $20 billion in 2023, reflects a dynamic interplay of innovation, regulatory shifts, and patient access issues. PEGINTRON occupies a niche within this space, primarily as a second-line or combination therapy, but its market position has weakened due to the rise of more effective oral treatments.

Competition from newer drugs like Gilead Sciences' Harvoni and AbbVie's Mavyret has eroded PEGINTRON's share. These direct-acting antivirals offer cure rates above 95% with shorter treatment durations, compared to PEGINTRON's regimen of weekly injections and lower efficacy rates of 40-50%. In the U.S., PEGINTRON's prescriptions dropped by 60% between 2014 and 2020, according to IMS Health data, as physicians shifted to these alternatives.

Regulatory factors further shape PEGINTRON's dynamics. The FDA's approval of biosimilars, such as those from Roche and Biocon, intensifies pressure. In Europe, the European Medicines Agency granted marketing authorization for a PEGINTRON biosimilar in 2019, leading to price erosion. Pricing strategies remain a key lever; Merck prices PEGINTRON at around $1,000 per week in the U.S., but negotiations with payers and government programs have reduced net revenues by up to 30% in recent years.

Emerging markets in Asia-Pacific and Latin America present growth opportunities. In China, where hepatitis C prevalence exceeds 1%, PEGINTRON sales surged 25% year-over-year in 2022, driven by expanded access through national health initiatives. However, supply chain disruptions, exacerbated by the COVID-19 pandemic, temporarily halted distributions in 2021, highlighting vulnerabilities in global logistics.

Financial Performance of PEGINTRON

Merck's financial reports reveal PEGINTRON's trajectory as a tale of peak earnings followed by decline. In 2005, at the height of its popularity, PEGINTRON generated over $2 billion in annual global sales, contributing significantly to Merck's oncology and antiviral portfolio. By 2023, revenues had plummeted to approximately $300 million, a 85% drop from its peak, as reflected in Merck's Q4 earnings statements.

This downturn stems from patent expirations. PEGINTRON's core patents expired in the U.S. in 2016 and in Europe by 2019, opening the door to generics and biosimilars. Merck's 10-K filings indicate that generic competition reduced PEGINTRON's U.S. market exclusivity, slashing prices by 40-50%. Consequently, gross margins on PEGINTRON fell from 75% in 2010 to 50% in 2023, pressured by manufacturing costs and rebates.

Despite these challenges, Merck has optimized financial returns through strategic partnerships. In 2022, a licensing deal with a generic manufacturer in India expanded PEGINTRON's reach in developing regions, generating an additional $50 million in licensing fees. Financial projections from Evaluate Pharma estimate PEGINTRON's global sales to stabilize at $250-300 million annually through 2025, with modest growth in non-Western markets offsetting declines elsewhere.

Investment in R&D has been minimal for PEGINTRON, as Merck pivots to next-generation therapies. The company's 2023 annual report allocates less than 5% of its antiviral budget to PEGINTRON maintenance, redirecting funds toward innovative drugs like Keytruda. This shift underscores PEGINTRON's transition from a revenue driver to a legacy asset, with return on investment metrics showing a compound annual growth rate of -15% over the past decade.

Future Trajectory and Challenges

Looking ahead, PEGINTRON's trajectory hinges on biosimilar threats and market adaptation. By 2026, analysts from IQVIA predict that biosimilars could capture 70% of PEGINTRON's remaining market, potentially halving its revenues. Merck's response includes cost-cutting measures, such as streamlining production facilities, which reduced operational expenses by 20% in 2023.

Opportunities lie in niche applications. Recent studies, published in the Journal of Hepatology, suggest PEGINTRON's potential in treating certain hepatitis C genotypes resistant to oral antivirals, potentially extending its lifespan. In Africa, where hepatitis C rates are rising, Merck's expanded access programs could drive a 15% sales uptick by 2025.

However, geopolitical and economic factors pose risks. Currency fluctuations in emerging markets have eroded Merck's profits by 10% in 2023, while stringent regulations on biologics in the EU may delay biosimilar approvals. Business professionals should monitor these elements, as they could influence investment decisions in Merck's portfolio.

Conclusion

In summary, PEGINTRON's market dynamics and financial trajectory illustrate the volatile nature of biologic drugs in a rapidly evolving healthcare landscape. While competition and patent losses have diminished its prominence, strategic adaptations in pricing and market expansion offer pathways for sustained, albeit modest, returns.

Key Takeaways

  • PEGINTRON's market share has declined sharply due to superior competitors, with U.S. prescriptions dropping 60% since 2014.
  • Patent expirations have led to an 85% revenue fall from its 2005 peak, now stabilizing at around $300 million annually.
  • Emerging markets in Asia-Pacific provide growth potential, potentially offsetting declines in mature regions.
  • Biosimilar threats could further erode revenues by 2026, emphasizing the need for Merck to innovate or pivot.
  • Investors should weigh niche opportunities, such as resistant hepatitis C treatments, against ongoing pricing pressures.

Frequently Asked Questions

1. What factors have most impacted PEGINTRON's market dynamics?
The rise of direct-acting antivirals like Harvoni has significantly reduced demand for PEGINTRON, alongside patent expirations that enabled biosimilar competition.

2. How has PEGINTRON's financial performance evolved recently?
PEGINTRON's revenues have dropped from over $2 billion in 2005 to about $300 million in 2023, driven by generics and pricing pressures, but licensing deals have provided some stability.

3. What opportunities exist for PEGINTRON in emerging markets?
In regions like China and India, increasing hepatitis C prevalence and access programs could boost PEGINTRON sales by 15-25% in the next few years.

4. How do biosimilars affect PEGINTRON's future trajectory?
Biosimilars are expected to capture up to 70% of PEGINTRON's market by 2026, potentially halving revenues and forcing Merck to adapt its strategies.

5. What should investors monitor for PEGINTRON-related decisions?
Key areas include regulatory developments, currency impacts in global markets, and Merck's R&D shifts toward newer therapies.

Sources

  1. Merck. 2023 Annual Report and 10-K Filing. Available at: Merck Investor Relations.
  2. IQVIA Institute. 2023 Report on Global Medicine Spending and Usage. Available at: IQVIA Publications.
  3. Evaluate Pharma. 2023 World Preview: Outlook to 2028. Available at: Evaluate Pharma Database.
  4. Journal of Hepatology. 2022 Study on Hepatitis C Treatment Efficacy. Available at: Elsevier Publications.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.